肝细胞癌患者血清趋化因子CXCR12和SA的表达及临床意义

Expression and Clinical Significance of Serum CXCR12 and SA in Patients with Hepatocarcinoma

目的探讨血清中趋化因子CXCR12和唾液酸sA在肝细胞癌中的表达及临床意义。方法应用酶联免疫吸附试验（ELISA）检测86例肝细胞癌患者血清趋化因子CXCR12和SA的表达水平，并与30例肝脏良性病变患者和23例健康对照者比较，分析其与肿瘤大小、TNM分期、分化程度、淋巴结转移以及AFP表达量的关系。结果肝细胞癌患者血清CXCR12表达量为5362．52±985．43pg／L，明显高于肝脏良性病变组（2784．46±976．33pg／L）和健康对照组（2768．89±980．42pg／L），差异均具有统计学意义（t=352．15，387．77，P〈0．05），而肝脏良性病变组与健康对照组比较差异无统计学意义（t=1．80，P〉0．05）；肝细胞癌患者血清SA的表达量为728．22±169．43mg／L，明显高于肝脏良性病变组（569．16±87．66mg／L）和健康对照组（564．26±89．23mg／L），差异均具有统计学意义（t=56．48，61．53，P〈0．05），而乳腺良性病变组与健康对照组比较差异无统计学意义（t=1．88，P〉0．05）。相关分析显示肝细胞癌患者血清CXCR12和SA水平之间呈正相关（r=0．634，P〈0．05）。肝细胞癌患者血清CXCR12和sA的表达水平与肿瘤大小、淋巴结转移、AFP水平及TNM分期明显相关（P〈0．05），但与肿瘤分化程度无明显相关性（P〉0．05）。结论CXCR12和SA可能在肝细胞癌的发生发展中起着重要作用，两者联合检测对于肝细胞癌的辅助诊断、疗效监测及预后判断具有一定的临床意义。

Objective To evaluate the expression and its clinical significance of serum CXCR12 and SA in patients with hepa- tocarcinoma. Methods 86 patients with hepatocarcinoma, 30 patients with benign hepatic diseases and 23 healthy controls were recruited in this study. The CXCR12 and SA levels were measured by ELISA in the serum of 86 patients with hepato- carcinoma,30 patients with benign hepatic diseases and 23 healthy controls. Results The level of serum CXCR12 in the hep- atocarcinoma group （5 362.52±985.43pg/L） was significantly higher than those in benign hepatic diseases （2 784.46 ± 976.33pg/L） and healthy controls （2 768.89±980.42pg/L） （t=352.15,387.77,P〈0.05）. The level of serum SA in the hepatocarcinoma group （728.22 ±169.43rag/L） was significantly higher than those in benign hepatic diseases （569.16 ±87.66mg/L） and healthy controls （564.26±89.23mg/L） （t=56. 48,61. 53,P〈0. 05）. No obvious difference in the levels of CXCR12 and SA was observed between benign hepatic diseases group and healthy control group （t= 1.80,1.88,P〈0.05）. Correlation analysis showed a positive correlation between the levels of CXCR12 and SA （r=0. 634, P〈0.05）. The levels of serum CXCR12 and SA were significantly associated with tumor size, lymph node metastasis, the expression of AFP and TNM stage （P〈0.05）, but were not associated with tumor differentiation （P〉0.05）. Conclusion CXCR12 and SA play a role in the tumorigenesis and development of hepatocarcinoma. Measuring of serum CXCR12 and SA may be a useful tool for diagnosis,effect monitoring and prognosis in hepatocarcinoma.